The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma

ConclusionOur results confirmed that lenvatinib is capable of improving patients ’ immune status, saving the effector cells from exhaustion status and inhibiting the number and function of immunosuppressive cells. The novel index CTL/Treg ratio qualifies as a predictor for the outcome of patients with lenvatinib therapy.

https://onlinelibrary.wiley.com/doi/10.1002/cam4.4312?af=R

Source: Cancer Medicine - October 4, 2021 Category: Cancer & Oncology Authors: Jie Zhu, Peiqi Fang, Chong Wang, Meixiu Gu, Baishen Pan, Wei Guo, Xinrong Yang, Beili Wang Tags: RESEARCH ARTICLE Source Type: research